UY26696A1 - Método para regular la angiogénesis utilizando proteína ryk - Google Patents

Método para regular la angiogénesis utilizando proteína ryk

Info

Publication number
UY26696A1
UY26696A1 UY26696A UY26696A UY26696A1 UY 26696 A1 UY26696 A1 UY 26696A1 UY 26696 A UY26696 A UY 26696A UY 26696 A UY26696 A UY 26696A UY 26696 A1 UY26696 A1 UY 26696A1
Authority
UY
Uruguay
Prior art keywords
ryk
anglogenesis
proteins
diseases
protein
Prior art date
Application number
UY26696A
Other languages
English (en)
Spanish (es)
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY26696A1 publication Critical patent/UY26696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UY26696A 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk UY26696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
UY26696A1 true UY26696A1 (es) 2001-12-28

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26696A UY26696A1 (es) 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (https=)
JP (1) JP2004527206A (https=)
AR (1) AR028424A1 (https=)
AU (1) AU2001261343A1 (https=)
CA (1) CA2408349A1 (https=)
CO (1) CO5300464A1 (https=)
DO (1) DOP2001000164A (https=)
EC (1) ECSP014068A (https=)
GT (1) GT200100079A (https=)
PE (1) PE20011218A1 (https=)
SV (1) SV2002000442A (https=)
UY (1) UY26696A1 (https=)
WO (1) WO2001085789A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
CA3229528A1 (en) * 2021-08-18 2023-02-23 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
NZ328371A (en) * 1994-12-23 1999-05-28 Ludwig Inst Cancer Res Method of detecting a ligand capable of binding the receptor protein neuroepithelial tyrosine kinase (nyk) and its use in therapeutic compositions
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
CA2348835A1 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
DOP2001000164A (es) 2002-05-15
EP1287121A2 (en) 2003-03-05
GT200100079A (es) 2001-12-31
SV2002000442A (es) 2002-07-03
CA2408349A1 (en) 2001-11-15
ECSP014068A (es) 2002-02-25
CO5300464A1 (es) 2003-07-31
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
AR028424A1 (es) 2003-05-07
WO2001085789A3 (en) 2002-05-16
WO2001085789A2 (en) 2001-11-15
PE20011218A1 (es) 2002-02-01

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
ECSP034548A (es) Derivados de quinolinona como inhibidores de tirosin quinasa
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
ES2080837T3 (es) Tratamiento de estados y enfermedades.
Philp et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
Tak et al. Oral submucous fibrosis: A review article on etiopathogenesis
UY26696A1 (es) Método para regular la angiogénesis utilizando proteína ryk
DK1343472T3 (da) Thixotropisk næsespray
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
EP1050309A4 (en) PROMOTER OF THE SECRETION OF NEUROTROPHIC FACTORS
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
ATE283058T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von dysphorie
UY26649A1 (es) Proteína que tiene actividad moduladora de angiogenesis
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
DE60002552D1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
Sajjad et al. The The Therapeutic Effects of Autologous Platelet-Rich Plasma Gel on Cutaneous Wound Healing in Rescued Horses: The Effects of Autologous Platelet-Rich Plasma Gel on skin Wound Healing in Horses
ATE302000T1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20131119